ProPhase Labs (PRPH) Stock Forecast, Price Target & Predictions
PRPH Stock Forecast
ProPhase Labs stock forecast is as follows: an average price target of $14.00 (represents a 432.32% upside from PRPH’s last price of $2.63) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.
PRPH Price Target
The average price target for ProPhase Labs (PRPH) is $14.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 432.32% upside from PRPH's last price of $2.63.
PRPH Analyst Ratings
According to 1 Wall Street analysts, ProPhase Labs's rating consensus is 'Hold'. The analyst rating breakdown for PRPH stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ProPhase Labs Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 17, 2022 | - | H.C. Wainwright | $14.00 | $7.60 | 84.21% | 432.32% |
The latest ProPhase Labs stock forecast, released on May 17, 2022 by H.C. Wainwright company, set a price target of $14.00, which represents a 84.21% increase from the stock price at the time of the forecast ($7.60), and a 432.32% increase from PRPH last price ($2.63).
ProPhase Labs Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $2.63 | $2.63 | $2.63 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of ProPhase Labs stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ProPhase Labs's last price of $2.63. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 21, 2022 | Dawson James | - | Neutral | Downgrade |
ProPhase Labs's last stock rating was published by Dawson James on Jul 21, 2022. The company Downgrade its PRPH rating from "null" to "Neutral".
ProPhase Labs Financial Forecast
ProPhase Labs Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 10 | Mar 09 | Mar 05 | Jun 04 | Mar 01 | Mar 00 | Dec 99 | Mar 98 | Jun 97 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $4.35M | $8.37M | - | $19.30M | $21.82M | $24.20M | $29.09M | $47.53M | $45.16M | $9.47M | $9.14M | $15.27M | $5.16M | $1.13M | $3.99M | - | - | - | - | - | - | - |
| Avg Forecast | $24.65M | $14.51M | $5.44M | $5.64M | $5.88M | $2.82M | $18.35M | $9.86M | $10.71M | $13.06M | $14.14M | $15.13M | $20.51M | $21.43M | $20.01M | $24.31M | $28.61M | $9.04M | $14.63M | $11.98M | $4.65M | $1.13M | $2.96M | $19.64M | $4.60M | $7.07M | $142.37K | $32.88M | $10.11M | $4.50M |
| High Forecast | $24.65M | $14.51M | $5.44M | $5.64M | $5.88M | $2.82M | $18.35M | $9.86M | $11.00M | $13.06M | $14.14M | $15.13M | $20.51M | $21.43M | $24.62M | $29.91M | $35.20M | $11.12M | $18.01M | $14.73M | $5.72M | $1.36M | $3.55M | $23.57M | $5.52M | $8.49M | $170.84K | $39.46M | $12.13M | $5.40M |
| Low Forecast | $24.65M | $14.51M | $5.44M | $5.64M | $5.88M | $2.82M | $18.35M | $9.86M | $10.40M | $13.06M | $14.14M | $15.13M | $20.51M | $21.43M | $15.41M | $18.72M | $22.03M | $6.96M | $11.27M | $9.22M | $3.58M | $904.00K | $2.37M | $15.72M | $3.68M | $5.66M | $113.89K | $26.31M | $8.09M | $3.60M |
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 9 | 7 | 12 | 16 | 7 | 8 | 19 | 19 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | 0.41% | 0.64% | - | 1.28% | 1.06% | 1.13% | 1.45% | 1.96% | 1.58% | 1.05% | 0.62% | 1.28% | 1.11% | 1.00% | 1.35% | - | - | - | - | - | - | - |
ProPhase Labs's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.86M, with a low forecast of $9.86M, and a high forecast of $9.86M. PRPH's average Quarter revenue forecast represents a 126.61% increase compared to the company's last Quarter revenue of $4.35M (Dec 23).
ProPhase Labs EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 10 | Mar 09 | Mar 05 | Jun 04 | Mar 01 | Mar 00 | Dec 99 | Mar 98 | Jun 97 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 9 | 7 | 12 | 16 | 7 | 8 | 19 | 19 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $-9.40M | $-6.48M | - | $2.16M | $-4.04M | $3.34M | $11.96M | $17.55M | $10.82M | $-2.97M | $-408.00K | $1.93M | $204.02K | $-2.17M | $-2.20M | - | - | - | - | - | - | - |
| Avg Forecast | $-2.22M | $-1.31M | $-489.99K | $-508.00K | $-529.62K | $-254.00K | $-1.65M | $2.43M | $-964.21K | $-1.18M | $-1.27M | $2.20M | $-1.85M | $1.94M | $-1.80M | $1.74M | $-2.58M | $-814.06K | $-1.32M | $1.38M | $-418.83K | $-2.17M | $-1.44M | $-209.67K | $-608.32K | $-593.38K | $-127.12M | $-3.42M | $2.91M | $2.02M |
| High Forecast | $-2.22M | $-1.31M | $-489.99K | $-508.00K | $-529.62K | $-254.00K | $-1.65M | $2.91M | $-936.30K | $-1.18M | $-1.27M | $2.65M | $-1.85M | $2.33M | $-1.39M | $2.09M | $-1.98M | $-626.77K | $-1.01M | $1.65M | $-322.47K | $-1.74M | $-1.15M | $-167.73K | $-486.65K | $-474.70K | $-101.70M | $-2.74M | $3.49M | $2.43M |
| Low Forecast | $-2.22M | $-1.31M | $-489.99K | $-508.00K | $-529.62K | $-254.00K | $-1.65M | $1.94M | $-991.22K | $-1.18M | $-1.27M | $1.76M | $-1.85M | $1.55M | $-2.22M | $1.39M | $-3.17M | $-1.00M | $-1.62M | $1.10M | $-515.30K | $-2.60M | $-1.72M | $-251.60K | $-729.98K | $-712.05K | $-152.54M | $-4.10M | $2.33M | $1.62M |
| Surprise % | - | - | - | - | - | - | - | - | 9.75% | 5.51% | - | 0.98% | 2.19% | 1.72% | -6.64% | 10.07% | -4.20% | 3.65% | 0.31% | 1.40% | -0.49% | 1.00% | 1.53% | - | - | - | - | - | - | - |
1 analysts predict PRPH's average Quarter EBITDA for Jun 23 to be $-1.27M, with a high of $-1.27M and a low of $-1.27M. This is -159.07% lower than ProPhase Labs's previous annual EBITDA (Mar 23) of $2.16M.
ProPhase Labs Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 10 | Mar 09 | Mar 05 | Jun 04 | Mar 01 | Mar 00 | Dec 99 | Mar 98 | Jun 97 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 9 | 7 | 12 | 16 | 7 | 8 | 19 | 19 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $-8.75M | $-5.14M | - | $550.00K | $-2.44M | $968.00K | $7.45M | $12.49M | $6.53M | $-3.98M | $-1.34M | $1.06M | $-978.00K | $-2.23M | $-2.19M | - | - | - | - | - | - | - |
| Avg Forecast | $-2.27M | $-3.21M | $-4.91M | $-4.72M | $-4.53M | $-5.86M | $-1.51M | $1.33M | $-4.91M | $-3.68M | $-2.64M | $1.21M | $472.20K | $1.76M | $3.34M | $955.07K | $8.31M | $-1.61M | $3.59M | $755.00K | $-377.76K | $-2.25M | $-1.44M | $-258.23K | $-608.32K | $-593.38K | $-127.12M | $-3.42M | $1.80M | $1.24M |
| High Forecast | $-2.27M | $-3.21M | $-4.91M | $-4.72M | $-4.53M | $-5.86M | $-1.51M | $1.59M | $-4.72M | $-3.68M | $-2.64M | $1.45M | $472.20K | $2.11M | $4.34M | $1.15M | $10.80M | $-1.13M | $4.66M | $906.00K | $-264.77K | $-1.80M | $-1.15M | $-206.58K | $-486.65K | $-474.70K | $-101.70M | $-2.74M | $2.16M | $1.49M |
| Low Forecast | $-2.27M | $-3.21M | $-4.91M | $-4.72M | $-4.53M | $-5.86M | $-1.51M | $1.06M | $-5.10M | $-3.68M | $-2.64M | $966.53K | $472.20K | $1.41M | $2.34M | $764.06K | $5.83M | $-2.09M | $2.52M | $604.00K | $-490.87K | $-2.70M | $-1.72M | $-309.87K | $-729.98K | $-712.05K | $-152.54M | $-4.10M | $1.44M | $990.00K |
| Surprise % | - | - | - | - | - | - | - | - | 1.78% | 1.40% | - | 0.46% | -5.18% | 0.55% | 2.23% | 13.08% | 0.79% | 2.48% | -0.37% | 1.40% | 2.59% | 0.99% | 1.52% | - | - | - | - | - | - | - |
ProPhase Labs's average Quarter net income forecast for Jun 23 is $-2.64M, with a range of $-2.64M to $-2.64M. PRPH's average Quarter net income forecast represents a -580.79% decrease compared to the company's last Quarter net income of $550.00K (Mar 23).
ProPhase Labs SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 10 | Mar 09 | Mar 05 | Jun 04 | Mar 01 | Mar 00 | Dec 99 | Mar 98 | Jun 97 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 9 | 7 | 12 | 16 | 7 | 8 | 19 | 19 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $8.02M | - | - | $9.50M | $15.89M | $9.91M | $8.11M | $12.50M | $1.66M | $7.42M | $5.82M | $7.59M | $4.08M | $2.60M | $4.31M | - | - | - | - | - | - | - |
| Avg Forecast | $12.77M | $7.52M | $2.82M | $2.92M | $3.05M | $1.46M | $9.51M | $9.54M | $5.55M | $6.77M | $7.33M | $8.68M | $10.63M | $4.09M | $10.37M | $6.86M | $14.83M | $4.68M | $7.58M | $5.42M | $2.41M | $585.63K | $2.82M | $8.07M | $1.91M | $4.90M | $73.78K | $27.36M | $4.71M | $1.35M |
| High Forecast | $12.77M | $7.52M | $2.82M | $2.92M | $3.05M | $1.46M | $9.51M | $11.45M | $5.70M | $6.77M | $7.33M | $10.41M | $10.63M | $4.91M | $12.76M | $8.23M | $18.24M | $5.76M | $9.33M | $6.51M | $2.96M | $702.75K | $3.38M | $9.69M | $2.29M | $5.88M | $88.54K | $32.83M | $5.65M | $1.62M |
| Low Forecast | $12.77M | $7.52M | $2.82M | $2.92M | $3.05M | $1.46M | $9.51M | $7.64M | $5.39M | $6.77M | $7.33M | $6.94M | $10.63M | $3.28M | $7.99M | $5.49M | $11.42M | $3.61M | $5.84M | $4.34M | $1.86M | $468.50K | $2.25M | $6.46M | $1.53M | $3.92M | $59.02K | $21.89M | $3.77M | $1.08M |
| Surprise % | - | - | - | - | - | - | - | - | 1.45% | - | - | 1.10% | 1.50% | 2.42% | 0.78% | 1.82% | 0.11% | 1.58% | 0.77% | 1.40% | 1.69% | 4.44% | 1.53% | - | - | - | - | - | - | - |
ProPhase Labs's average Quarter SG&A projection for Mar 24 is $9.54M, based on 1 Wall Street analysts, with a range of $7.64M to $11.45M. The forecast indicates a 18.98% rise compared to PRPH last annual SG&A of $8.02M (Dec 23).
ProPhase Labs EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 10 | Mar 09 | Mar 05 | Jun 04 | Mar 01 | Mar 00 | Dec 99 | Mar 98 | Jun 97 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 9 | 7 | 12 | 16 | 7 | 8 | 19 | 19 | 9 |
| EPS | - | - | - | - | - | - | - | - | $-0.48 | $-0.30 | - | $0.03 | $-0.15 | $0.06 | $0.48 | $0.81 | $0.42 | $-0.24 | $-0.09 | $0.07 | $0.23 | $-0.15 | $-0.17 | - | - | - | - | - | - | - |
| Avg Forecast | $-0.12 | $-0.17 | $-0.26 | $-0.25 | $-0.24 | $-0.31 | $-0.08 | $-0.28 | $-0.26 | $-0.20 | $-0.14 | $-0.10 | $0.03 | $0.19 | $0.18 | $0.39 | $0.44 | $-0.09 | $0.19 | $0.20 | $-0.02 | $-0.15 | $-0.07 | $-0.12 | $-0.02 | $-0.16 | $-0.32 | $0.34 | $0.18 | $0.09 |
| High Forecast | $-0.12 | $-0.17 | $-0.26 | $-0.25 | $-0.24 | $-0.31 | $-0.08 | $-0.28 | $-0.25 | $-0.20 | $-0.14 | $-0.10 | $0.03 | $0.19 | $0.23 | $0.50 | $0.57 | $-0.06 | $0.25 | $0.27 | $-0.01 | $-0.12 | $-0.05 | $-0.09 | $-0.01 | $-0.13 | $-0.26 | $0.41 | $0.22 | $0.11 |
| Low Forecast | $-0.12 | $-0.17 | $-0.26 | $-0.25 | $-0.24 | $-0.31 | $-0.08 | $-0.28 | $-0.27 | $-0.20 | $-0.14 | $-0.10 | $0.03 | $0.19 | $0.12 | $0.27 | $0.31 | $-0.11 | $0.13 | $0.14 | $-0.03 | $-0.18 | $-0.08 | $-0.14 | $-0.03 | $-0.19 | $-0.39 | $0.27 | $0.14 | $0.07 |
| Surprise % | - | - | - | - | - | - | - | - | 1.85% | 1.54% | - | -0.30% | -6.00% | 0.32% | 2.72% | 2.10% | 0.95% | 2.82% | -0.47% | 0.34% | -11.50% | 1.00% | 2.43% | - | - | - | - | - | - | - |
According to 1 Wall Street analysts, ProPhase Labs's projected average Quarter EPS for Jun 23 is $-0.14, with a low estimate of $-0.14 and a high estimate of $-0.14. This represents a -566.67% decrease compared to PRPH previous annual EPS of $0.03 (Mar 23).
ProPhase Labs Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LMDX | LumiraDx | $0.02 | $1.50 | 7400.00% | Buy |
| DRIO | DarioHealth | $0.87 | $10.75 | 1135.63% | Buy |
| STIM | Neuronetics | $0.95 | $8.00 | 742.11% | Buy |
| PRPH | ProPhase Labs | $2.63 | $14.00 | 432.32% | Hold |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $2.77 | $6.00 | 116.61% | Buy |
| STRR | Star Equity | $4.02 | $8.00 | 99.00% | Buy |
| BDSX | Biodesix | $1.80 | $3.00 | 66.67% | Buy |
| SHC | Sotera Health Company | $16.66 | $16.93 | 1.62% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
PRPH Forecast FAQ
Is ProPhase Labs a good buy?
No, according to 1 Wall Street analysts, ProPhase Labs (PRPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of PRPH's total ratings.
What is PRPH's price target?
ProPhase Labs (PRPH) average price target is $14 with a range of $14 to $14, implying a 432.32% from its last price of $2.63. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ProPhase Labs stock go up soon?
According to Wall Street analysts' prediction for PRPH stock, the company can go up by 432.32% (from the last price of $2.63 to the average price target of $14), up by 432.32% based on the highest stock price target, and up by 432.32% based on the lowest stock price target.
Can ProPhase Labs stock reach $4?
PRPH's average twelve months analyst stock price target of $14 supports the claim that ProPhase Labs can reach $4 in the near future.
What are ProPhase Labs's analysts' financial forecasts?
ProPhase Labs's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $36.91M (high $36.91M, low $36.91M), average EBITDA is $-11.057K (high $474.02K, low $-496K), average net income is $-10.57M (high $-10.305M, low $-10.836M), average SG&A $23.56M (high $25.47M, low $21.65M), and average EPS is $-0.91 (high $-0.91, low $-0.91). PRPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $50.24M (high $50.24M, low $50.24M), average EBITDA is $-4.525M (high $-4.525M, low $-4.525M), average net income is $-15.11M (high $-15.11M, low $-15.11M), average SG&A $26.04M (high $26.04M, low $26.04M), and average EPS is $-0.8 (high $-0.8, low $-0.8).
Did the PRPH's actual financial results beat the analysts' financial forecasts?
Based on ProPhase Labs's last annual report (Dec 2022), the company's revenue was $122.65M, beating the average analysts forecast of $86.26M by 42.18%. Apple's EBITDA was $28.81M, beating the average prediction of $31.72K by 90725.69%. The company's net income was $18.46M, beating the average estimation of $6.52M by 183.12%. Apple's SG&A was $46.41M, beating the average forecast of $31.96M by 45.22%. Lastly, the company's EPS was $1.17, beating the average prediction of $0.777 by 50.64%. In terms of the last quarterly report (Dec 2023), ProPhase Labs's revenue was $4.35M, missing the average analysts' forecast of $10.7M by -59.36%. The company's EBITDA was $-9.402M, beating the average prediction of $-964K by 875.10%. ProPhase Labs's net income was $-8.751M, beating the average estimation of $-4.911M by 78.20%. The company's SG&A was $8.02M, beating the average forecast of $5.55M by 44.60%. Lastly, the company's EPS was $-0.48, beating the average prediction of $-0.26 by 84.62%